This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Try These ETF Strategies to Play the Market Optimism for 2H21
by Sweta Jaiswal, FRM
Here we discuss certain ETF strategies to help investors gain from the optimism surrounding the expectations of a strong Wall Street run in the second half of 2021.
A Quick Guide to the 25 Cheapest ETFs
by Sweta Killa
Keeping the importance of expense ratio in mind, we have highlighted the 25 cheapest ETFs currently on the market and have AUM of more than $50 million.
Top ETF Investing Areas to Park Your Money in June
by Sweta Jaiswal, FRM
Let's look into some ETF areas that make winning choices for investors this June.
Small-Cap ETF (SCHA) Hits New 52-Week High
by Sweta Killa
This small-cap ETF hits a new 52-week high. Are more gains in store for this ETF?
ETF Strategies to Play the Drop in New US COVID-19 Cases
by Sweta Jaiswal, FRM
Here we discuss some ETF strategies that investors can play amid the upbeat outlook for the U.S. market.
ETF Strategies to Play the US Market Optimism
by Sweta Jaiswal, FRM
Here we discuss some ETF strategies that investors can play amid the upbeat outlook for the U.S. market.
ETF Areas That Are Looking Attractive in April
by Sweta Jaiswal, FRM
Let's take a look at some ETF areas that are presenting some great investment opportunities for April considering the current market scenario.
A Spread of Small-Cap ETFs Touching New Heights
by Sweta Killa
We have highlighted a number of small-cap ETFs that hit all-time highs in the last trading session and are among the popular choices.
ETF Areas to Consider as Senate Passes COVID-19 Relief Bill
by Sweta Jaiswal, FRM
Here we highlight some popular ETFs from varied sectors that can benefit from Biden's $1.9-trillion stimulus plan.
ETF Strategies to Gain From the Stimulus & Vaccine Optimism
by Sweta Jaiswal, FRM
Let's look at some ETF strategies to help investors gain from optimism surrounding another trench of coronavirus-aid package and coronavirus vaccine development.